Brand | Abnova |
Product type | Primary antibodies |
Reactivity | Human,Non-Human Primates |
Host species | Mouse |
Applications | IP,Flow Cyt |
Brand: | Abnova |
Reference: | MAB4361 |
Product name: | FCGR3A monoclonal antibody, clone LNK16 (PE) |
Product description: | Mouse monoclonal antibody raised against native FCGR3A. |
Clone: | LNK16 |
Isotype: | IgG1 |
Gene id: | 2214 |
Gene name: | FCGR3A |
Gene alias: | CD16|CD16A|FCG3|FCGR3|FCGRIII|FCR-10|FCRIII|FCRIIIA|IGFR3 |
Gene description: | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) |
Immunogen: | Native purified FCGR3A from normal human peripheral blood granulocytes. |
Form: | Liquid |
Recommend dilutions: | Flow Cytometry (20 ul in human blood cells 100 ul in whole blood or 106 cells in a suspension) The optimal working dilution should be determined by the end user. |
Storage buffer: | In PBS (0.2% BSA, 0.09% sodium azide) |
Storage instruction: | Store in the dark at 4°C. Do not freeze. Avoid prolonged exposure to light. Aliquot to avoid repeated freezing and thawing. |
Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
Conjugate tag: | PE |
Product type: | Primary antibodies |
Host species: | Mouse |
Antigen species / target species: | Human |
Specificity: | This antibody reacts with CD16, a low affinity receptor for aggregated IgG (FcgammaRIII antigen). CD16 exists in two different isoforms: CD16a (FcgammaRIIIA; 50-65 KDa; expressed on NK-cells, monocytes and macrophages) and CD16b (FcgammaRIIIB; 48 KDa; mainly expressed on neutrophils). |
Reactivity: | Human,Non-Human Primates |
Application image: | ![]() |
Application image note: | Surface staining of human peripheral blood cells with FCGR3A monoclonal antibody, clone LNK16 (PE) (Cat # MAB4361). |
Applications: | IP,Flow Cyt |
Shipping condition: | Blue Ice |
Publications: | IgE-mediated activation of NK cells through Fc gamma RIII.Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T. J Immunol. 2003 Mar 15;170(6):3054-8. |